Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro

Tamoxifen (TAM) remains the adjuvant therapy of choice for pre-menopausal women with ERα-positive breast cancer. Resistance and recurrence remain, however, a major challenge with many women relapsing and subsequently dying. The insulin-like growth factor (IGF) axis is involved in breast cancer patho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawsawi, Yousef, Humphries, Matthew P., Wright, Alexander, Berwick, Angelene, Shires, Mike, Al-Kharobi, Hanaa, El-Gendy, Reem, Jove, Maria, Twelves, Chris, Speirs, Valerie, Beattie, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078002/
https://www.ncbi.nlm.nih.gov/pubmed/27050076
http://dx.doi.org/10.18632/oncotarget.8534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078002/
https://www.ncbi.nlm.nih.gov/pubmed/27050076
http://dx.doi.org/10.18632/oncotarget.8534

Ejemplares similares